Individual Patient Expanded Access to CA102N

Advanced or Metastatic Colorectal Cancer (mCRC) Clinical Trial

Official title:

Expanded Access to CA102N in One Patient Who Completed at Least 12 Cycles of Combination Therapy of CA102N Plus Lonsurf in Clinical Study Number of HS-CA102N-101

Clinical Trial Details — Status: Temporarily not available

Administrative data

• NCT number: NCT05274204
• Other study ID #: HS-CA102N-102
• Status: Temporarily not available

Study information

• Verified date: February 2023
• Source: Holy Stone Healthcare Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.

Description:

In the individual patient expanded access, the subject who was enrolled in Phase 1 trial (Study Number: HS-CA102N-101) Part 2 (dose expansion) and had completed at least 12 treatment cycles with CA102N combined with trifluridine /tipiracil (LONSURF) will be provided access to treatment with CA102N (0.72 mg/kg Nimesulide Equivalent of CA102N).

Recruitment information / eligibility

• Status: Temporarily not available
• Enrollment: 0
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

- Exclusion Criteria: -

Related Conditions & MeSH terms

• Advanced or Metastatic Colorectal Cancer (mCRC)
• Colorectal Neoplasms

Intervention

Drug:
• CA102N

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Holy Stone Healthcare Co., Ltd